Advertisement

Robotic Pelvic and Retroperitoneal Lymph Node Dissection

  • Steven V. Kardos
  • Jonathan Yamzon
Chapter

Abstract

Pelvic lymph node dissection (PLND) and retroperitoneal lymph node dissection (RPLND) remain critical components of many urologic disease processes and procedures. Dissection may provide accurate lymph node staging and confer potential therapeutic benefit. For prostate cancer management, lymph node dissection at prostatectomy provides an opportunity for staging and, when compared with other treatment options, has been shown to have a possible therapeutic benefit by lower cancer-specific death rates [1–3]. In the management of testicular cancer, RPLND is considered an established treatment option, depending on the histologic subtype and clinical stage of the disease. The robotic platform allows for a full therapeutic dissection with equivalent oncologic outcomes and shorter convalescence when compared with open RPLND [4, 5]. Finally, in the management of patients with locally advanced renal masses (T3–T4) or unfavorable clinical and/or pathologic features, a template lymph node dissection may offer improved survival [6–8].

Keywords

Prostate cancer Renal cell carcinoma Upper tract urothelial carcinoma Testicular cancer Nonseminomatous germ cell tumor Seminoma Pelvic lymph node dissection PLND Retroperitoneal lymph node dissection RPLND 

References

  1. 1.
    Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol. 2012;187:1259–65.CrossRefGoogle Scholar
  2. 2.
    Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68:121–5.CrossRefGoogle Scholar
  3. 3.
    Hyndman ME, Mullins JK, Pavlovich CP. Pelvic node dissection in prostate cancer: extended, limited, or not at all? Curr Opin Urol. 2010;20:211–7.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. Testicular cancer. (Version 2. 2016).Google Scholar
  6. 6.
    Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, et al. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60:1212–20.CrossRefGoogle Scholar
  7. 7.
    Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Gitlitz BJ, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076–83.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Liebovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am. 2008;35:673–8.CrossRefGoogle Scholar
  9. 9.
    Yuh BE, Ruel NH, Mejia R, Novara G, Wilson TG. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU Int. 2013;112:81–8.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014;65:918–27.CrossRefGoogle Scholar
  11. 11.
    Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, et al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol. 2007;177:876–81.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Nicolai N, MIceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R. A simple model for predicting nodal metastasis in patients with clinical stage 1 nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol. 2004;171:172–6.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37:582–94.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol. 1998;160:1347–52.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Abdul-Muhsin HM, L'Esperance JO, Fischer K, Woods ME, Porter JR, Castle EP. Robot-assisted retroperitoneal lymph node dissection in testicular cancer. J Surg Oncol. 2015;112:736–40.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Williams SB, Lau CS, Josephson DY. Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage 1 nonseminomatous germ cell testicular cancer. Eur Urol. 2011;60:1299–302.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Cheney SM, Andrews PE, Leibovich BC, Castle EP. Robot assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int. 2015;115:114–20.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59:18–23.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 2011;60:776–83.CrossRefGoogle Scholar
  20. 20.
    Seisen T, Shariat SF, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, Rouprêt M. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2017;35(4):535–48.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Jamal JE, Jarrett TW. The current role of lymph node dissection in the management of renal cell carcinoma. Int J Surg Oncol. 2011;2011:816926.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Steven V. Kardos
    • 1
  • Jonathan Yamzon
    • 2
  1. 1.Urology and Urologic Oncology, Northeast Medical Group, Yale New Haven HealthFairfieldUSA
  2. 2.Department of SurgeryCity of Hope National Medical CenterDuarteUSA

Personalised recommendations